| - | - | - |
|---|---|---|
| Product Group | : | Antiparasitics |
| Pharmaceutical Form | : | Solution for Injection |
| Active Ingredient | : | Buparvakuon |
| Target Animal | : | Cattle |
| Package Form | : | 50 ml Amber Colored Glass Flacons |
COMPOSITION
It is a clear, red colored solution containing 50 mg buparvaquone per ml.
PHARMACOLOGICAL PROPERTIES
Pharmacodynamic Properties
Buparvaquone is a second generation hydroxynaphthoquinone derivative chemically derived from parvaquone.
The effect of buparvaquone in all Theileria species is to destroy the organism by inhibiting the biochemical stages of the respiratory mechanism of parasite. It accomplishes this by inhibiting electron transport in the respiratory chain, which is vital for the parasite.
Pharmacokinetics Properties
Buparvaquone has a longer plasma half-life due to the tertiary-butyl bond in its structure and is metabolized slowly due to the cyclohexyl ring at the 4-position. Maximum plasma concentration is reached within 3-3.5 hours following intramuscular injection. The half-life is 26.44 ± 2.81 hours after administration. Parvakuvil Solution for Injection is largely excreted in the feces after being degraded in the liver. recovering animals develop antibodies specific to the strain causing the disease.
AREA OF USE/INDICATIONS
It is used for the treatment of all forms of Theileriosis caused by Theileria annulata, T. parva, T. bovis, T. mutans, T. sergenti in cattle.
Buparvaquone shows specific efficiency to Theileria. Since Parvakuvil Solution for Injection is effective on both the flizont and red blood cell stages of these blood parasites, it can be administered during the incubation period of the disease and after clinical symptoms appear.
USAGE AND DOSAGE
It is administered only deep intramuscularly to neck area;
Pharmacological dose: 2,5 mg/kg body weight.
Practical dose: 1 ml/20 kg body eight.
Usually, single dose is sufficient but in severe cases, the same dose can be applied after 48 or 72 hours.
When it is necessary to use more than 10 ml, it is recommended to divide the total amount and inject it in two separate places.
SPECIAL CLINICAL INFORMATION AND SPECIAL WARNINGS FOR TARGET SPECIES
- In severe cases of theileriosis, treatment may be repeated.
- Anemia is characteristic in theileriosis cases and anemia treatment should be taken into consideration.
- Sick animals should be treated with a suitable acaricide and existing ticks should be controlled.
Use during pregnancy and lactation: It is recommended not to be used in pregnant animals. The safety of this product in cattle during pregnancy and lactation or in breeding animals has not been established. Laboratory studies in rabbits and rats with the excipient N-methylpyrrolidone have shown evidence of fetotoxic effects.
ADVERSE EFFECTS
Transient muscle spasms may occur after the injection. There may also be a local, painless, edematous, temporary swelling at the injection site.
DRUG INTERACTIONS
Since theileriosis has a suppressive effect on the immune system, vaccination should not be done during the disease and convalescence period.
Should not be mixed with other medicinal products.
SYMPTOMS OF OVERDOSE, PRECAUTIONS AND ANTIDOTE
Safe at the reported therapeutic dose. There is no specific antidote.
WITHDRAWAL PERIODS
Meat: 42 days.
Milk: It is not used in cows from which milk is obtained for human consumption
CONTRAINDICATIONS
Do not use intravenously or subcutaneously.
GENERAL WARNINGS
Consult a veterinarian before use and if any unexpected effects occur. Keep out of reach of children and away from foodstuffs.
PRECAUTIONS TO BE TAKEN BY THE ADMINISTRATOR AND WARNINGS FOR VETERINARY SURGEON
Please avoid contact with the drug and wash your hands after use. In case of eye or skin contact, rinse the area throughly with water.
Laboratory studies in rabbits and rats with the excipient N-methylpyrrolidone have shown evidence of fetotoxic effects. Women of childbearing age, pregnant or likely to become pregnant who will administer the product should exercise utmost care and take all precautions to prevent accidental self-injection and contact with the product.
STORAGE CONDITIONS AND SHELF LIFE
Before and after opening, the product should be stored below 25°C, in the original packages, without being frozen or placed in the refrigerator. Protect from sunlight. Shelf life is 2 years. It should be used within 28 days after opening.
DISPOSAL AFTER USE AND WARNINGS FOR NON-TARGET SPECIES
Used or remaining product should be disposed of according to the relevant regulations.
COMMERCIAL PRESENTATION FORM
It is presented in 50 ml amber-colored glass vials with cardboard box.
PLACE AND CONDITIONS OF SALE
It is sold in pharmacies and veterinary clinics with a veterinarian's prescription. (VSP)
APPROVAL DATE OF LEAFLET: 13.10.2025
MARKETING AUTHORIZATION DATE AND NO: 17.05.2006 – 016/0017
MARKETING AUTHORIZATION HOLDER
VİLSAN Veteriner İlaçları Tic. ve San. A.Ş.
Balıkhisar Mah. Balıkhisar Köy İçi Küme Evleri No:765A Akyurt/Ankara-Türkiye
MANUFACTURER COMPANY
VİLSAN Veteriner İlaçları Tic. ve San. A.Ş.
Balıkhisar Mah. Balıkhisar Köy İçi Küme Evleri No:765A Akyurt/Ankara-Türkiye
Made in Turkiye
